Our Treatments

Medicine We Develop

Medicine We Develop
Oral for PWSPrader-Willi Syndrome
Topical for Psoriasis
Oral for IBDCrohn's & Colitis
Our treatments

Creating Better Treatments and Changing Lives

EPM is committed to developing a series of new therapeutic solutions based on cannabinoid acids which provide alternative treatments for patients. This is the driving force behind EPM’s research program. Although cannabinoid acids are potential treatments for a wide range of diseases, currently, EPM focuses on two main therapeutic conditions based on its lead molecules: metabolic disorders (Prader-Willi Syndrome) and inflammatory skin disease (Psoriasis).

Oral FormulationPWS
Phase 1 clinical trial in H1 2023
Estimated incidence (births)
Our Treatments

Prader-Willi Syndrome

Selected formulation
Oral

Expected clinical trail timeline

Phase 1 clinical trial anticipated in H1 2023


EPM’s Potential Solution
Results demonstrated that treatment with EPM301 in preclinical study on a mouse model, has reduced food intake and body weight, improved ambulatory activity, normalized lipid, glucose and insulin levels and more. These results give promise to a drug based on EPM301 which will be able to regulate hunger in PWS people, as well as improve metabolic systems homeostasis.

Topical formulationPsoriasis
Phase 1 Clinical trial during 2023
Patients worldwide
Our treatments

Psoriasis

Selected formulation
Topical

Expected clinical trail timeline
Phase 1 clinical trail in healthy volunteers anticipated during 2023

EPM's potential solution
The treatment is based on EPM301 and has been evaluated in an ex vivo model of inflammatory skin disease. When applied topically, it displayed similar activity to hydrocortisone.

Oral formulationCrohn's & Colitis
Phase 1 Clinical trial TBD
Patients in Europe
Our Treatments

Inflammatory Bowel Disease

Selected formulation
Oral

Expected clinical trail timeline
TBD

EPM's potential solution
The treatment is based on EPM301 and has been evaluated in both acute (DSS induced mouse colitis) and chronic (IL-10 knock-out mouse) animal models of IBD and has shown similar activity to prednisone (acute model) and anti-TNFa mAb (chronic model) when administered by gavage.